Q3 2023 Results - Reimagining Medicine slide image

Q3 2023 Results - Reimagining Medicine

Company overview Financial review Innovation: Pipeline overview Financial performance Cardiovascular Immunology Conclusions Cardiovascular Appendix Innovation: Clinical trials Neuroscience Oncology References Abbreviations Other 44 Investor Relations | Q3 2023 Results NOVARTIS | Reimagining Medicine
View entire presentation